We could not find any results for:
Make sure your spelling is correct or try broadening your search.
The current NVV1 market cap is 937.02M. The company's latest EPS is USD -4.5885 and P/E is -1.83.
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Revenue | 18.66M | 475.6M | 1.15B | 1.98B | 983.71M |
Operating Income | -129.6M | -416.72M | -1.69B | -644.74M | -566.51M |
Net Income | -132.69M | -418.26M | -1.74B | -657.94M | -545.06M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Total Assets | 172.96M | 1.58B | 2.58B | 2.26B | 1.8B |
Total Liabilities | 358.97M | 955.27M | 2.93B | 2.89B | 2.51B |
Total Equity | -186.02M | 627.21M | -351.67M | -634.08M | -716.93M |
Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Operating | -136.62M | -42.54M | 322.95M | -415.94M | -713.97M |
Investing | 38.49M | -377.78M | 100.15M | -92.99M | -58.81M |
Financing | 98.38M | 984.76M | 461.71M | 324.99M | 4.47M |
Market Cap | 937.02M |
Price to Earnings Ratio | -1.83 |
Price to Sales Ratio | 1.02 |
Price to Cash Ratio | 1.76 |
Price to Book Ratio | -1.39 |
Dividend Yield | - |
Shares Outstanding | 118.79M |
Average Volume (1 week) | 13.91k |
Average Volume (1 Month) | 37.02k |
52 Week Change | 54.61% |
52 Week High | 24.96 |
52 Week Low | 3.313 |
Spread (Intraday) | 0.03 (0.42%) |
Company Name | Novavax Inc |
Address |
1209 orange street wilmington, delaware 19801 |
Website | https://www.novavax.com |
Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions